Opendata, web and dolomites

D2P SIGNED

Diabeloop to Patients: An Artificial Pancreas solution to improve the balance, safety and autonomy of 20 million people

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 D2P project word cloud

Explore the words cloud of the D2P project. It provides you a very rough idea of what is the project "D2P" about.

basis    telemonitoring    regulation    severe    regulating    specificities    loop    hyperglycaemia    day    personalised    innovation    cells    adjustments    adoption    age    producing    connected    pump    diseases    intelligence    handset    countries    burden    professional    models    diabeloop    monitoring    hosting    people    artificial    dose    pancreas    closed    automatically    calculate    netherlands    stressful    first    t1d    storage    destruction    performances    device    hypoglycaemia    dblg1    sweden    half    countless    optimisation    diabetes    delivered    model    exchange    million    insulin    coma    beta    anyone    complications    foreign    fainting    market    amputations    clinicians    solution    glucose    industrialisation    renal    data    death    blindness    mimic    physiological    upgrade    france    generation    goals    daily    suggest    worldwide    causes    reduce    validate    made    secured    healthcare    20    treatment    customisation    function    heart    continuous    seizures    periods    begin    healthy    algorithms    situations    sensor    telemedicine    appropriate    components    core    integrates    identification    patient    alleviate    autoimmune    breakthrough    patients    complementary   

Project "D2P" data sheet

The following table provides information about the project.

Coordinator
DIABELOOP 

Organization address
address: 155-157 COURS BERRIAT
city: GRENOBLE
postcode: 38028
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 2˙793˙190 €
 EC max contribution 1˙955˙233 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DIABELOOP FR (GRENOBLE) coordinator 1˙955˙233.00

Map

 Project objective

20 million people worldwide are affected by type 1 diabetes (T1D), an autoimmune condition leading to the destruction of beta cells of the pancreas producing insulin. T1D causes severe complications: short terms - seizures and fainting that could result in coma or even death; long terms - blindness, amputations, renal failure, heart diseases. T1D can occur to anyone and half of the cases begin before age 20. T1D patients have to manage their diabetes on a daily basis, facing countless stressful situations.

Diabeloop’s “artificial pancreas” solution aims to mimic the glucose regulating function of a healthy pancreas. The core of our “artificial pancreas” solution is an artificial intelligence: algorithms based on physiological models continuously calculate the most appropriate and personalised dose of insulin. Insulin is then automatically delivered to the patient. Diabeloop goals are to reduce hypoglycaemia and hyperglycaemia periods, alleviate the day-to-day burden and avoid long-term complications.

Diabeloop’s first generation solution (DBLG1) is integrated in a closed-loop system made of three components: a continuous glucose monitoring sensor, a connected insulin pump, and a handset hosting algorithms and controlling the pump. Diabeloop’s solution integrates a telemedicine program through highly secured data exchange, storage and healthcare professional identification. Clinicians may access the patients’ data and suggest treatment adjustments as necessary, for an improved system customisation and long-term regulation. During the phase 2 project, we scale up and target a European adoption of our breakthrough innovation. We focus on France, the Netherlands and Sweden, 3 countries with complementary specificities to validate our model: adaptation of the device to foreign market, optimisation of performances, telemonitoring upgrade and industrialisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "D2P" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "D2P" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

STURSKIN (2018)

Innovative products by using tanned sturgeon skin

Read More